Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis

• Published in: Kidney international Vol. 100; no. 6; p. 1316
• Main Authors: Gulati, Kavita, Edwards, Helena, Prendecki, Maria, Cairns, Thomas D, Condon, Marie, Galliford, Jack, Griffith, Megan, Levy, Jeremy B, Tam, Frederick W K, Tanna, Anisha, Pusey, Charles D, McAdoo, Stephen P
• Format: Journal Article
• Language: English
• Published: United States 01-12-2021
• Subjects: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy; Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide - adverse effects; Drug Therapy, Combination; Humans; Immunosuppressive Agents - adverse effects; Plasma Exchange; Remission Induction; Retrospective Studies; Rituximab - adverse effects; granulomatosis with polyangiitis; pulmonary-renal syndrome; rapidly progressive glomerulonephritis; microscopic polyangiitis; vasculitis; plasmapheresis; immunosuppression
• ISSN: 1523-1755
• DOI: 10.1016/j.kint.2021.08.025

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis can present with life-threatening lung-kidney syndromes. However, many controlled treatment trials excluded patients with diffuse alveolar hemorrhage or severely impaired glomerular filtration rates, and so the optimum treatment in these cases is unclear. In this retrospective cohort study, we report the outcomes of 64 patients with life-threatening disease treated with a combination regimen of rituximab, low-dose intravenous cyclophosphamide, oral glucocorticoids, and plasma exchange. At entry, the median estimated glomerular filtration rate was 9 mL/min, 47% of patients required dialysis, and 52% had diffuse alveolar hemorrhage. All patients received a minimum of seven plasma exchanges, and the median cumulative doses of rituximab, cyclophosphamide, and glucocorticoid were 2, 3, and 2.6 g, respectively, at six months. A total of 94% of patients had achieved disease remission (version 3 Birmingham Vasculitis Activity Score of 0) at this time point, and 67% of patients who required dialysis recovered independent kidney function. During long-term follow-up (median duration 46 months), overall patient survival was 85%, and 69% of patients remained free from end-stage kidney disease, which compares favorably to a historic cohort with severe disease treated with a conventional induction regimen. Combination treatment was associated with prolonged B cell depletion and low rates of relapse; 87% of patients were in continuous remission at month 36. The serious infection rate during total follow-up was 0.28 infections/patient/year, suggesting that combination treatment is not associated with an enduring risk of infection. Thus, we suggest that combination immunosuppressive therapy may permit glucocorticoid avoidance and provide rapid and prolonged disease control in patients with severe ANCA-associated vasculitis.